FDA opens abbreviated approval pathway for interchangeable biosimilars

The FDA has proposed a regulatory path for biosimilar biologics that are interchangeable with the reference product.

(RSS generated with FetchRss)

FULL ARTICLE: http://zpr.io/Phi4e